Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cell Mol Life Sci. 2009 Apr;66(7):1163-77. doi: 10.1007/s00018-008-8539-7.

Therapeutic protein kinase inhibitors.

Author information

  • 1Department of Biochemical Pharmacology, Pfizer Global Research & Development, Pfizer La Jolla Laboratories, 10777 Science Center Drive, San Diego, CA 92121, USA. stephan.grant@pfizer.com

Abstract

Protein kinase inhibitors represent an important and still emerging class of targeted therapeutic agents. Drug discovery and development strategies have explored numerous approaches to target the inhibition of protein kinase signaling. This review will highlight some of the strategies that have led to the successful clinical development of therapeutic protein kinase inhibitors, particularly as anticancer drugs. Some notable advances have been made in the development of novel protein and oligonucleotide-based biologics that target growth factor or receptor tyrosine kinases. Also, advances have been made in the rational design of small-molecule inhibitors that target unique kinase conformational forms and binding sites, and have specific kinase selectivity profiles. A review will also be given of some of the potential clinical toxicities and adverse side-effects associated with these kinase-targeted drugs. Therapeutic protein kinase inhibitors have been highly beneficial to cancer patients and offer the promise of future therapies for other diseases as well.

PMID:
19011754
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk